IKT News and Press, Inhibikase Therapeutics Inc. From 05/08/23

Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023 PR Newswire BOSTON and ATLANTA , May 8, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company dev...

Inhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference PR Newswire BOSTON and ATLANTA , May 4, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company de...

Inhibikase Therapeutics Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial in Parkinson's Disease PR Newswire - State-of-the-art biomarker analyses a hallmark of the 201 study - BOSTON and ATLANTA , April 26...

Inhibikase Therapeutics to Present at the 2023 Planet MicroCap Showcase PR Newswire BOSTON and ATLANTA , April 21, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing...

2023-04-03 13:29:06 ET Inhibikase Therapeutics, Inc. (IKT) Q4 2022 Earnings Conference Call April 3, 2023 08:00 ET Company Participants Alex Lobo - Stern Investor Relations Milton Werner - President & Chief Executive Officer Joe Frattaroli - Chief Financial O...

2023-03-31 08:52:50 ET Inhibikase Therapeutics press release ( NASDAQ: IKT ): FY GAAP EPS of -$0.72. Revenue of $0.1M (-96.8% Y/Y). Cash, cash equivalents and marketable securities were $23.1 million as of December 31, 2022. Selling, general and administrative expe...

Inhibikase Therapeutics Reports Full Year 2022 Financial Results and Highlights Recent Period Activity PR Newswire BOSTON and ATLANTA , March 31, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharma...

Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023 PR Newswire BOSTON and ATLANTA , March 23, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-st...

Inhibikase Therapeutics to Present at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders PR Newswire BOSTON and ATLANTA , March 21, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("In...

2023-03-16 09:33:00 ET When searching for penny stocks to buy or penny stocks to watch, it’s good to focus on catalysts. Typically valued under $5 per share, these stocks generally attract small and new investors. Even with the glitz and glamour that comes with massive breakouts,...